Abstract
Amyloid beta (Aβ), especially Aβ oligomers, is important in early Alzheimer’s disease (AD) pathogenesis. AD-associated inflammation has generally been considered as a secondary response to the pathological lesions evoked by Aβ oligomers in the early stage of pathogenesis. We studied the levels of plasma Aβ monomers, Aβ oligomers, and soluble tumor necrosis factor α receptors (sTNFRs) in 120 controls, 32 amnestic mild cognitive impairment (aMCI) patients, and 90 mild AD patients. The plasma Aβ monomer, oligomer and sTNFR levels were measured by ELISA. We observed that the Aβ oligomer levels in mild AD patients were significantly higher than those in aMCI (200.8±83.8 versus 93.9±23.3, P<0.05) and healthy subjects (200.8±83.8 versus 70.0±60.9, P<0.05). The sTNFR levels in the plasma of aMCI and mild AD patients were significantly higher than the levels of control subjects. Moreover, the levels of both sTNFR1 and sTNFR2 were significantly correlated with Aβ oligomer levels in aMCI (sTNFR1r= 0.376, P= 0.034; sTNFR2r= 0.367, P= 0.039) and mild AD patients (sTNFR1r= 0.471, P< 0.001; sTNFR2 r= 0.407, P< 0.001). More importantly, changes in Aβ oligomer and sTNFR levels accurately differentiated mild AD patients from control subjects, supporting these levels might be potential diagnostic biomarkers for aMCI and AD.
Keywords: Alzheimer's disease, amyloid-beta oligomers, biomarker, ELISA, soluble tumor necrosis factor receptor.
Current Alzheimer Research
Title:Plasma Amyloid-β Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Biomarkers of AD
Volume: 11 Issue: 4
Author(s): Jinbiao Zhang, Mao Peng and Jianping Jia
Affiliation:
Keywords: Alzheimer's disease, amyloid-beta oligomers, biomarker, ELISA, soluble tumor necrosis factor receptor.
Abstract: Amyloid beta (Aβ), especially Aβ oligomers, is important in early Alzheimer’s disease (AD) pathogenesis. AD-associated inflammation has generally been considered as a secondary response to the pathological lesions evoked by Aβ oligomers in the early stage of pathogenesis. We studied the levels of plasma Aβ monomers, Aβ oligomers, and soluble tumor necrosis factor α receptors (sTNFRs) in 120 controls, 32 amnestic mild cognitive impairment (aMCI) patients, and 90 mild AD patients. The plasma Aβ monomer, oligomer and sTNFR levels were measured by ELISA. We observed that the Aβ oligomer levels in mild AD patients were significantly higher than those in aMCI (200.8±83.8 versus 93.9±23.3, P<0.05) and healthy subjects (200.8±83.8 versus 70.0±60.9, P<0.05). The sTNFR levels in the plasma of aMCI and mild AD patients were significantly higher than the levels of control subjects. Moreover, the levels of both sTNFR1 and sTNFR2 were significantly correlated with Aβ oligomer levels in aMCI (sTNFR1r= 0.376, P= 0.034; sTNFR2r= 0.367, P= 0.039) and mild AD patients (sTNFR1r= 0.471, P< 0.001; sTNFR2 r= 0.407, P< 0.001). More importantly, changes in Aβ oligomer and sTNFR levels accurately differentiated mild AD patients from control subjects, supporting these levels might be potential diagnostic biomarkers for aMCI and AD.
Export Options
About this article
Cite this article as:
Zhang Jinbiao, Peng Mao and Jia Jianping, Plasma Amyloid-β Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Biomarkers of AD, Current Alzheimer Research 2014; 11 (4) . https://dx.doi.org/10.2174/1567205011666140317103222
DOI https://dx.doi.org/10.2174/1567205011666140317103222 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
STAIR Narrative Therapy: A Skills Focused Approach to Trauma-Related Distress
Current Psychiatry Reviews Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Disorders of Mineral Metabolism in the Newborn
Current Pediatric Reviews Bis-coumarin Derivatives and Their Biological Activities
Current Topics in Medicinal Chemistry The Start of a New Era for Stroke Treatment: Mechanical Thrombectomy Devices
Current Neurovascular Research RNA Interference as a Tool for Alzheimers Disease Therapy
Mini-Reviews in Medicinal Chemistry Orthostatic Hypotension: Evaluation and Treatment
Cardiovascular & Hematological Disorders-Drug Targets Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Wii Balance Board: Reliability and Clinical Use in Assessment of Balance in Healthy Elderly Women
CNS & Neurological Disorders - Drug Targets Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy
Central Nervous System Agents in Medicinal Chemistry Pharmacological Approaches of Alzheimer's Disease: An Update
Current Drug Therapy Prediction of miRNA in Human MHC that Encodes Different Immunological Functions Using Support Vector Machines
Current Bioinformatics Combining Feature Extraction Methods to Assist the Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core
Current Topics in Medicinal Chemistry Rehab of NAD(P)-Dependent Enzymes with NAD(P)-Based Inhibitors
Current Medicinal Chemistry Molecular Docking, DFT Studies and ADMET Simulations for Evaluating Already Approved FDA Drugs as Inhibitors for SARS-Cov-2 RNADependent Polymerase
Letters in Drug Design & Discovery Strong Association of Lipid Metabolism Related MicroRNA Binding Sites Polymorphisms with the Risk of Late Onset Alzheimer’s Disease
Current Neurovascular Research Inflammation as a Therapeutic Target for Various Deadly Disorders: A Review
Current Drug Targets Heart Rate Variability Analysis at Coronary Artery Disease and Angina Pectoris
Recent Patents on Cardiovascular Drug Discovery